Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
Gino K. In, James Hu, William W. Tseng
Therapeutic Advances in Medical Oncology (2017) Vol. 9, Iss. 8, pp. 533-550
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 11, pp. 1423-1432
Closed Access | Times Cited: 306
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Yihebali Chi, Zhiwei Fang, Xiaonan Hong, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 21, pp. 5233-5238
Open Access | Times Cited: 272
TP53 in bone and soft tissue sarcomas
Elizabeth Thoenen, Amanda Curl, Tomoo Iwakuma
Pharmacology & Therapeutics (2019) Vol. 202, pp. 149-164
Open Access | Times Cited: 111
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Amanda R. Dancsok, Nokitaka Setsu, Dongxia Gao, et al.
Modern Pathology (2019) Vol. 32, Iss. 12, pp. 1772-1785
Open Access | Times Cited: 76
Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines
Tânia Capelôa, Zohra Benyahia, Luca X. Zampieri, et al.
Seminars in Cell and Developmental Biology (2019) Vol. 98, pp. 181-191
Closed Access | Times Cited: 63
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R. Abdul Razak, Sebastian Bauer, Cristina Suárez, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 6, pp. 1087-1097
Open Access | Times Cited: 48
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
Erlinda M. Gordon, Sant P. Chawla, Walter Andree Tellez, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 906-906
Open Access | Times Cited: 18
Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
Jun Gong, Jessica Yan, Charles Forscher, et al.
Drug Design Development and Therapy (2018) Vol. Volume 12, pp. 777-786
Open Access | Times Cited: 53
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Brian A. Van Tine, Matthew Ingham, Steven Attia, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 20, pp. 2404-2414
Open Access | Times Cited: 4
Correlation between METTL3 overexpression and 18F-FDG uptake in patients with soft tissue sarcoma
Tong Wu, Jinghui Xie, Hongbo Feng, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA
Alina Muenchow, Sandra K. Weller, Clemens Hinterleitner, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 8
Open Access | Times Cited: 24
Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms
Lichuan Wu, Ke Ye, Sheng Jiang, et al.
Marine Drugs (2021) Vol. 19, Iss. 9, pp. 488-488
Open Access | Times Cited: 21
A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade
Andrej Ozaniak, Jitka Smetanová, Robin Bartolini, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 7, pp. 3789-3801
Closed Access | Times Cited: 15
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
Sant P. Chawla, Walter Andree Tellez, Hripsime Chomoyan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Treatment of Rare Epithelial Ovarian Tumors
Lauren P. Cobb, David M. Gershenson
Hematology/Oncology Clinics of North America (2018) Vol. 32, Iss. 6, pp. 1011-1024
Closed Access | Times Cited: 24
Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
Eisuke Kobayashi, Yoichi Naito, Naofumi Asano, et al.
Japanese Journal of Clinical Oncology (2019) Vol. 49, Iss. 10, pp. 938-946
Open Access | Times Cited: 23
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity
J. Herzog, F. von Klot-Heydenfeldt, Sami Khalaf Jabar, et al.
Sarcoma (2016) Vol. 2016, pp. 1-6
Open Access | Times Cited: 22
Aldoxorubicin in Soft Tissue Sarcomas
Florence Chamberlain, Robin L. Jones, Sant P. Chawla
Future Oncology (2019) Vol. 15, Iss. 13, pp. 1429-1435
Closed Access | Times Cited: 20
Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcoma
Teruya Kawamoto, Hitomi Hara, Masayuki Morishita, et al.
Clinical & Experimental Metastasis (2020) Vol. 37, Iss. 4, pp. 509-517
Closed Access | Times Cited: 20
Antibody Conjugates for Sarcoma Therapy: How Far along Are We?
Letizia Polito, Giulia Calafato, Massimo Bortolotti, et al.
Biomedicines (2021) Vol. 9, Iss. 8, pp. 978-978
Open Access | Times Cited: 17
Impact of sarcopenia in advanced and metastatic soft tissue sarcoma
Dennis Strassmann, Bennet Hensen, Viktor Grünwald, et al.
International Journal of Clinical Oncology (2021) Vol. 26, Iss. 11, pp. 2151-2160
Open Access | Times Cited: 16
B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
Ilona Hagelstein, Monika Engel, Clemens Hinterleitner, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Jiangang Liu, David S. Moura, Robin L. Jones, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 11, pp. 2598-2608
Closed Access | Times Cited: 2
Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma
Sei Morinaga, Qinghong Han, KOHEI MIZUTA, et al.
Anticancer Research (2024) Vol. 44, Iss. 9, pp. 3777-3783
Open Access | Times Cited: 2
Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma
Bruna V. Jardim‐Perassi, Wei Mu, Su‐Ning Huang, et al.
Theranostics (2021) Vol. 11, Iss. 11, pp. 5313-5329
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top